The Anti-CD38 Antibody Therapy in Multiple Myeloma
| Autor: | Federico Vozella, Maria Teresa Petrucci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty CD38+ medicine.drug_class Review Monoclonal antibody Ixazomib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine immune system diseases Internal medicine hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Molecular Targeted Therapy monoclonal antibodies (MoAb) Multiple myeloma Lenalidomide Clinical Trials as Topic Bortezomib business.industry SLAMF7 Antibodies Monoclonal Drug Synergism General Medicine medicine.disease Pomalidomide Carfilzomib ADP-ribosyl Cyclase 1 multiple myeloma 030104 developmental biology Treatment Outcome chemistry 030220 oncology & carcinogenesis Immunotherapy business medicine.drug |
| Zdroj: | Cells |
| ISSN: | 2073-4409 |
| Popis: | Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the majority of MM patients experience several relapses and receive multiple lines of treatment. Currently, bortezomib and lenalidomide are the core component of treatment both at the time of diagnosis and at the relapse as well as the new proteasome inhibitors (PIs), such as carfilzomib and ixazomib, and the next-generation immunomodulatory drug, pomalidomide, are now available for patients in relapse. In addition, drugs with a different mechanism of action, such as the histone deacetylase inhibitor and the monoclonal antibodies (MoAb) targeting SLAMF7 or CD38, are a part of the anti-myeloma armamentarium and are very important for heavily pretreated or double refractory to a PI and IMiD patients. In this paper, we focus on the efficacy as well as toxicities of CD38 antibodies used both as a single agent and in combination as multiple myeloma treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |